1989
DOI: 10.1093/clinids/11.4.655
|View full text |Cite
|
Sign up to set email alerts
|

Visceral Leishmaniasis (Kala-Azar) as an Opportunistic Infection in Patients Infected with the Human Immunodeficiency Virus in Spain

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

3
35
0
1

Year Published

1993
1993
2016
2016

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 104 publications
(39 citation statements)
references
References 23 publications
3
35
0
1
Order By: Relevance
“…Bone marrow invasion can result in severe anemia, leukopenia, and thrombocytopenia (4,5). In the absence of effective treatment, persons with kala-azar become immunosuppressed and typically die, often by a secondary bacterial or other infection (6)(7)(8)(9).…”
Section: Introductionmentioning
confidence: 99%
“…Bone marrow invasion can result in severe anemia, leukopenia, and thrombocytopenia (4,5). In the absence of effective treatment, persons with kala-azar become immunosuppressed and typically die, often by a secondary bacterial or other infection (6)(7)(8)(9).…”
Section: Introductionmentioning
confidence: 99%
“…Additionally, visceral leishmaniasis is accompanied by high titers ofantileishmanial antibodies, likely to be T cell dependent. Finally, murine models of L. donovani-induced visceral disease have demonstrated that T cells are required for successful chemotherapy despite a lack of detectable antigen-specific proliferative activity or lymphokine secretion (8), observations which find their counterpart in the resistance to therapy of visceral leishmaniasis in patients with coexisting HIV infection (9).…”
Section: Introductionmentioning
confidence: 99%
“…1 Microbiologic cure is observed in less than half the cases and relapses are frequent. [6][7][8][9] In this setting, toxic effects of Sb V have seldom been reported in previous studies. 6,10,11 However, the dose of Sb V used in these patients was limited to a maximum of 850 mg/day.…”
mentioning
confidence: 95%
“…6,10,11 However, the dose of Sb V used in these patients was limited to a maximum of 850 mg/day. [6][7][8][9][10][11][12] Therefore, we assume that a low dose was administered. Thus, few data are available on efficacy and safety of the currently recommended Sb V dosing schedule to treat VL in HIV-1-infected individuals.…”
mentioning
confidence: 99%